Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
The Mundipharma network of independent associated companies has launched the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway.
The US affiliate of specialty pharmaceutical company Indivior has introduced an authorized generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US.
Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.
British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.
Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.
Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.
GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.
Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.